Peter H. Ehrenberg Partner

New YorkNew Jersey
T 212.204.8697 | F 973.597.2351

Chair, Corporate Department

Peter’s work for high-stakes corporate clients combines strategic thinking, creative solutions, and old-fashioned common sense. Clients say he’s “in a league of his own: outstanding in every respect, extremely knowledgeable, thoughtful and very hardworking” (Chambers).

Peter represents issuers in private and public offerings of debt and equity securities, as well as acquirers and sellers of businesses. He also counsels public companies in regard to compliance and public reporting responsibilities, including duties under the Sarbanes-Oxley Act and other corporate governance reforms. 

Peter’s success in these areas stems from an unflagging commitment to his clients’ business success. He maintains hands-on control of each transaction, weighing dozens of options to determine the strategy that will lead to the best outcome. Clients laud his responsiveness, accessibility, and caring attitude. Many stay with him for the long term, through multiple companies and positions.

A proactive leader, Peter was a mentor to the founder of Lowenstein’s Tech Group and helped champion the firm’s Patent Department early on. He currently serves as chair of the firm’s corporate department.

Representative Engagements

Represented FTP Power LLC (sPower), the largest independent owner, operator, and developer of utility scale solar assets in the United States, in its $2.1 billion sale to affiliates of The AES Corporation and Alberta Investment Management Corporation by Fir Tree Partners and sPower’s minority owners.
Represented Tower International, Inc. (NYSE: TOWR), and its subsidiaries, in a $561.5 million refinancing consisting of a $361.5 million term loan facility agented by Citibank, N.A. and a $200 million revolving credit facility agented by JPMorgan Chase Bank, N.A.
Represented Lakeland Bancorp, Inc. in the merger of Harmony Bank into Lakeland Bank, a wholly-owned subsidiary of our client Lakeland Bancorp, Inc.
View More...

Other Distinctions

  • Chambers USA: America’s Leading Lawyers for Business – Listed in the corporate and M&A sections and lauded as the “gold standard” for corporate and M&A law.

  • The Best Lawyers in America (1987-2018) – Listed in the corporate and M&A sections.


SEC Issues Statement on Conflict Minerals Rule; Not Much Changes
Capital Markets & Securities Client Alert, April 13, 2017
Peter Ehrenberg, Steven Skolnick, John Hogoboom, Laura Kuntz, Alan Wovsaniker
Market Trends: Risk Factors
Lexis Practice Advisor, March 31, 2017
Laura Kuntz, Peter Ehrenberg
SEC Shortens Settlement Cycle from T+3 to T+2
Capital Markets & Securities Client Alert, March 23, 2017
Peter Ehrenberg, Steven Skolnick, John Hogoboom, Laura Kuntz, Alan Wovsaniker
View More...

Press Mentions

Bloomberg View cites Forbes Tech article by Ed Zimmerman, Peter Ehrenberg, and Valeska Pederson Hintz on SEC Rule 701 in its discussion of robot funds and bank regulation. , Bloomberg View , August 4, 2016
Lowenstein Sandler’s Tech Group represented Flatiron Health in a funding round led by the global pharmaceutical company Roche. According to the New York Times, the financing was $175M. Flatiron Health is a big data health tech startup that gathers and analyzes data on cancer treatments and produces software to enhance the quality of patient care. Flatiron’s OncologyCloud software platform connects patients, physicians, life sciences companies, and researchers. As part of this deal, Roche will also purchase several of Flatiron’s subscription-based software products. The Lowenstein team included Ed Zimmerman, Peter Ehrenberg, Eric Weiner, Nicholas Mehler, Darren Bilotto, Jocqui Kaup, Matt Holbreich, and Jeff Silberman. , January 11, 2016
Lowenstein Sandler represented Covis Pharma S.á.r.l and Covis Injectables S.á.r.l, global specialty pharmaceutical companies providing therapeutic solutions to patients, in their all-cash $1.2 billion sale of assets to Concordia Healthcare Corp (TSX: CXR), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The acquisition closed on April 21, 2015. The Lowenstein deal team was led by Ethan A. Skerry, Robert G. MinionPeter H. Ehrenberg and also included Nicholas G. Mehler, Sam E. Khan, Jean N. Samedi, Brian Shemesh, Jack D. Sidorov, Jeffrey M. Shapiro, Hilla Shimshoni, Lowell A. Citron, Theodore C. Sica, Brian A. Silikovitz, Christina Iafe, Katie Cobb, Brandon Greenblatt and Gene Cheval. , April 21, 2015
View More...

Related Areas

Capital Markets & Securities
Corporate Governance & Compliance
Mergers & Acquisitions
Transactions & Advisory Group


Yale Law School ( J.D. , 1973 ) , Editor, Yale Law Journal
Trinity College ( B.A. , 1969 ) , Phi Beta Kappa

Bar Admissions

New York
New Jersey
District of Columbia

Court Admissions

1973 , U.S. Court of Appeals, Federal Circuit


  • American Bar Association